ABIONYX Pharma announces unanimous approval of all resolutions put to the vote at its Combined General Meeting
June 27 2024 - 12:22PM
Business Wire
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible),
a new generation biotech company dedicated to the discovery and
development of innovative therapies based on the world’s only
natural recombinant apoA-I, announces that all resolutions
presented at its Combined General Meeting were unanimously
approved.
Among the resolutions adopted were the renewal of the mandate of
M. Christian Chavy as Director and the mandate of BPI FRANCE
Participations as censor, represented by M. Olivier Martinez, for a
3-year term. Shareholders also approved the renewal of the share
buyback program and of the liquidity contract.
ABIONYX Pharma would like to thank all shareholders present,
represented or having voted by post for their commitment and
support at this General Meeting.
The minutes of the General Meeting and the results of the votes
by resolution are available on the Company's website in the
Shareholder Meeting section.
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on
developing innovative medicines for diseases where there is no
effective or existing treatment, even the rarest ones. The company
expedites the development of novel therapeutics through an
extensive expertise in lipid science and a differentiated
apoA-I-based technology platform. ABIONYX Pharma is committed to
radically improving treatment outcomes in Sepsis and critical
care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240627988446/en/
NewCap Investor relations Louis-Victor Delouvrier Nicolas
Fossiez abionyx@newcap.eu +33 (0)1 44 71 98 53 NewCap Media
relations Arthur Rouillé abionyx@newcap.eu +33 (0)1 44 71 94 98
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
From Nov 2023 to Nov 2024
